## Stella Flampouri

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/712628/publications.pdf

Version: 2024-02-01

623734 552781 26 853 14 26 citations g-index h-index papers 26 26 26 979 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	National Cancer Institute Workshop on Proton Therapy for Children: Considerations Regarding Brainstem Injury. International Journal of Radiation Oncology Biology Physics, 2018, 101, 152-168.	0.8	138
2	Effective Dose Reduction to Cardiac Structures Using Protons Compared With 3DCRT and IMRT in Mediastinal Hodgkin Lymphoma. International Journal of Radiation Oncology Biology Physics, 2012, 84, 449-455.	0.8	126
3	Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines. Blood, 2018, 132, 1635-1646.	1.4	86
4	Consolidative Involved-Node Proton Therapy for Stage IA-IIIB Mediastinal Hodgkin Lymphoma: Preliminary Dosimetric Outcomes From a Phase II Study. International Journal of Radiation Oncology Biology Physics, 2012, 83, 260-267.	0.8	72
5	Evidence-based Review on the Use of Proton Therapy in Lymphoma From the Particle Therapy Cooperative Group (PTCOG) Lymphoma Subcommittee. International Journal of Radiation Oncology Biology Physics, 2017, 99, 825-842.	0.8	66
6	Involved-Node Proton Therapy in Combined Modality Therapy for Hodgkin Lymphoma: Results of a Phase 2 Study. International Journal of Radiation Oncology Biology Physics, 2014, 89, 1053-1059.	0.8	60
7	The Meaningless Meaning of Mean Heart Dose in Mediastinal Lymphoma in the Modern Radiation Therapy Era. Practical Radiation Oncology, 2020, 10, e147-e154.	2.1	51
8	Proton therapy for skull-base chondrosarcoma, a single-institution outcomes study. Journal of Neuro-Oncology, 2019, 142, 557-563.	2.9	41
9	Linear energy transfer distributions in the brainstem depending on tumour location in intensity-modulated proton therapy of paediatric cancer. Acta Oncol $ ilde{A}^3$ gica, 2017, 56, 763-768.	1.8	36
10	Comparison of Techniques for Involved-Site Radiation Therapy in Patients With Lower Mediastinal Lymphoma. Practical Radiation Oncology, 2019, 9, 426-434.	2.1	22
11	Proton Therapy for Pediatric Hodgkin Lymphoma. Pediatric Blood and Cancer, 2016, 63, 1522-1526.	1.5	20
12	ITV-Based Robust Optimization for VMAT Planning of Stereotactic Body Radiation Therapy of Lung Cancer. Practical Radiation Oncology, 2019, 9, 38-48.	2.1	16
13	Rationale and early outcomes for the management of thymoma with proton therapy. Translational Lung Cancer Research, 2018, 7, 106-113.	2.8	15
14	Comparing Breath Hold and Free Breathing during Intensity-Modulated Radiation Therapy and Proton Therapy in Patients with Mediastinal Hodgkin Lymphoma. International Journal of Particle Therapy, 2017, 3, 492-496.	1.8	15
15	Pulmonary Toxicity Following Proton Therapy for Thoracic Lymphoma. International Journal of Radiation Oncology Biology Physics, 2017, 99, 494-497.	0.8	14
16	Radiation doses to brain substructures associated with cognition in radiotherapy of pediatric brain tumors. Acta Oncológica, 2019, 58, 1457-1462.	1.8	13
17	Importance of baseline PET/CT imaging on radiation field design and relapse rates in patients with Hodgkin lymphoma. Advances in Radiation Oncology, 2017, 2, 197-203.	1.2	11
18	Intrafractional Displacement of Cardiac Substructures Among Patients With Mediastinal Lymphoma or Lung Cancer. Advances in Radiation Oncology, 2019, 4, 500-506.	1.2	11

#	Article	IF	CITATIONS
19	Proton therapy for lung cancer. Thoracic Cancer, 2012, 3, 109-116.	1.9	10
20	Protonâ€based chemoradiation for synchronous bilateral nonâ€smallâ€cell lung cancers: A case report. Thoracic Cancer, 2013, 4, 198-202.	1.9	8
21	Impact of intrafraction prostate motion on clinical target coverage in proton therapy: A simulation study of dosimetric differences in two delivery techniques. Journal of Applied Clinical Medical Physics, 2019, 20, 67-73.	1.9	6
22	Cardiac MRI for Detecting Early Cardiac Toxicity after Proton Therapy for Hodgkin Lymphoma. International Journal of Particle Therapy, 2019, 5, 41-44.	1.8	5
23	Selective nodal irradiation of regionally advanced nonâ€smallâ€cell lung cancer with proton therapy and IMRT: A dosimetric comparison. Thoracic Cancer, 2012, 3, 169-174.	1.9	4
24	Evaluating Cardiac Biomarkers after Chemotherapy and Proton Therapy for Mediastinal Hodgkin Lymphoma. International Journal of Particle Therapy, 2017, 4, 35-38.	1.8	4
25	Impact of unfavorable factors on outcomes among inoperable stage II-IV Nonsmall cell lung cancer patients treated with proton therapy. Acta OncolÁ³gica, 2019, 58, 313-319.	1.8	2
26	Selection of Mediastinal Lymphoma Patients for Proton Therapy Within the Proton Collaborative Group Registry. American Journal of Clinical Oncology: Cancer Clinical Trials, 2021, 44, 269-274.	1.3	1